This is an ambitious and well-rounded project. It brings together academic resources and industry players to create a strong public-private partnership. The project will enable Montpellier
to position itself in the field of bio-production at a European level, thus forming an excellence site that
supports and attracts other biotech companies, while also facilitating and accelerating French R&D on advanced therapy drugs.
It incorporates all the research units in the Montpellier area as well as national and international expertise. The project will meet the requirements of
the Health Innovation 2030 plan, covering everything from fundamental research to bio-production to the creation of a care center for our patients.
Several facilities will be built starting in 2024
to provide the necessary space and to develop this strategic activity. The Thomas Platter building is the first one for the project. It will be built on the hospital site, close to teams, patients, and technical facilities. With this architectural undertaking, the Montpellier CHU University Hospital will continue to support the development of innovative new therapies.
Montpellier has many assets
for pursuing the development of innovative therapeutic drugs. This includes therapeutic products derived from biological matter in the human body. Thanks to scientific progress over the past 20 years, these treatments will play an increasingly important role for patients whose pathologies are currently inadequately or poorly treated.
This innovation revolves around the
IRMB Institute (Institute for Regenerative Medicine and Biotherapy),
INSERM research laboratories, high-tech research platforms funded with support from Montpellier Métropole and the Occitanie Region, clinical teams carrying out large-scale European projects, and a University Hospital Federation.
Medical research in cell therapy is the future of health worldwide.
MedXCell, the project’s leader, seeks to transform healthcare by developing
new therapies that are affordable and accessible to as many people as possible.
Reinforcing life science activity in the Montpellier area by raising 2.5 M€ from institutional partners (ARIS, Banque Populaire du Sud, Caisse d’Epargne, Crédit Agricole), along with initial funding from the MedXCell group, the company will set up
a new facility in the Cap Sigma building (partnership between Montpellier Métropole and SERM) starting in 2022, and continue its development in the
future Thomas Platter building planned for 2025.
A building offering a range of complementary functions:
-
Outpatient clinic on the first floor
-
Incubator for startups involved with medical research and innovation
-
Offices for MedXCell
-
Production areas for treatments in compliance with GMP (Good Manufacturing Practices)
-
Food service area with dedicated outdoor spaces
Project overview in numbers:
-
Total surface area: 5,150 m² (55,434 sq. feet)
-
Building permit submitted on June 30, 2022
-
Delivery planned in 2025
About MedXCell
MedXCell Group is a French/Swiss biotech group established in 2018 and dedicated to cellular therapies. Starting as a single biotech firm operating from Switzerland, the MedXCell group is now developing a Startup Studio model based in Montpellier, built on strong partnerships with national research institutions such as the CHU University Hospital Center, University of Montpellier, SATT AxLR, CNRS, INSERM, and international organizations such as EPFL (Swiss Federal Institute of Technology Lausanne).
